Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail (Details)

v2.4.0.6
Condensed Consolidated Financial Statement Detail (Details)
3 Months Ended 9 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2012
USD ($)
Sep. 30, 2011
USD ($)
Sep. 30, 2012
USD ($)
Sep. 30, 2011
USD ($)
Sep. 30, 2012
Mar. 09, 2012
Dec. 31, 2011
USD ($)
Sep. 30, 2012
Five year warrants issued in February 2010 [Member]
USD ($)
Dec. 31, 2011
Five year warrants issued in February 2010 [Member]
USD ($)
Feb. 01, 2010
Five year warrants issued in February 2010 [Member]
USD ($)
Sep. 30, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
Sep. 30, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
Mar. 09, 2012
Five year warrants issued in March 2012 [Member]
Mar. 01, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
Sep. 30, 2012
Warrants issued to private investors [Member]
USD ($)
Dec. 31, 2011
Warrants issued to private investors [Member]
USD ($)
Jun. 30, 2009
Warrants issued to private investors [Member]
USD ($)
Sep. 30, 2012
Options Contract [Member]
USD ($)
Sep. 30, 2012
Options Contract [Member]
USD ($)
Sep. 30, 2012
Options Contract [Member]
EUR (€)
Sep. 30, 2012
Option Contract 1 [Member]
EUR (€)
Sep. 30, 2012
Option Contract 2 [Member]
EUR (€)
Sep. 30, 2012
Common stock options and restricted stock units [Member]
Sep. 30, 2011
Common stock options and restricted stock units [Member]
Sep. 30, 2012
Common stock options and restricted stock units [Member]
Sep. 30, 2011
Common stock options and restricted stock units [Member]
Sep. 30, 2012
Convertible preferred stock [Member]
Sep. 30, 2011
Convertible preferred stock [Member]
Sep. 30, 2012
Convertible preferred stock [Member]
Sep. 30, 2011
Convertible preferred stock [Member]
Sep. 30, 2012
Warrants for common stock [Member]
Sep. 30, 2011
Warrants for common stock [Member]
Sep. 30, 2012
Warrants for common stock [Member]
Sep. 30, 2011
Warrants for common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                                                                    
Antidilutive securities excluded from computation of earnings per share (in shares) 22,356,000 5,644,000 18,730,000 5,535,000                                     5,730,000 4,036,000 5,788,000 3,837,000 0 0 0 90,000 16,626,000 1,608,000 12,942,000 1,608,000
Cash and cash equivalents [Abstract]                                                                    
Demand deposit $ 11,400,000   $ 11,400,000       $ 21,100,000                                                      
Money market funds 30,800,000   30,800,000       27,200,000                                                      
Short-term Investments [Abstract]                                                                    
Short-term investments, U.S. treasury securities 16,996,000   16,996,000       0 [1]                                                      
Derivative [Line Items]                                                                    
Notional amount of derivative liability                                       15,000,000                            
Derivative, amount of hedged item                                         1,500,000 15,000,000                        
Number of foreign exchange option contracts                                   2 2                              
Derivative, premiums                                     1,500,000                              
Derivative fair value                                   500,000 500,000                              
Derivative, loss   300,000   100,000                           100,000 700,000                              
Accrued liabilities [Abstract]                                                                    
Accrued management incentive compensation 2,821,000   2,821,000       4,096,000                                                      
Accrued payroll and other benefits 2,510,000   2,510,000       3,007,000                                                      
Accrued clinical trial costs 3,940,000   3,940,000       140,000                                                      
Accrued severance payments 642,000   642,000       1,207,000                                                      
Other 1,754,000   1,754,000       1,562,000                                                      
Total 11,667,000   11,667,000       10,012,000 [1]                                                      
Class of Warrant or Right [Line Items]                                                                    
Warrants outstanding (in shares)         14,743,697 14,834,577       1,260,000     14,834,577       347,826                                  
Exercise price (in dollars per share)               $ 10.5   $ 10.5 $ 1.76 $ 1.76   $ 1.76 $ 19.5   $ 19.5                                  
Fair value of warrant liability 32,100,000   32,100,000           300,000   32,100,000 32,100,000   6,400,000   100,000                                    
Gain (loss) on revaluation of warrant liability               $ (200,000)     $ 9,000,000 $ 26,000,000     $ (100,000)                                      
[1] The condensed consolidated balance sheet as of December 31, 2011 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011.